Comparison of the difference between amosar and norvasc tablets for the treatment of high blood pressure

Both Amosar and Norvasc are used to treat high blood pressure, but they belong to two different classes of medications that work by different mechanisms to achieve this goal. Understanding the differences between them helps determine the most appropriate medication for each patient based on their health condition and individual needs.

Amosar Tablets Ingredients

Amosar tablets contain the active ingredient losartan. Losartan belongs to a class of angiotensin II receptor blockers (ARBs). These medications work by blocking the effect of a chemical in the body that constricts blood vessels, helping them dilate and lower blood pressure.

Norvasc Tablets Ingredients

Norvasc tablets contain the active ingredient amlodipine besylate. Amlodipine belongs to a class of calcium channel blockers, which relaxes blood vessels, facilitating blood flow and lowering blood pressure. Norvasc is used as a single medication to treat high blood pressure and angina.

Information about Amosar tablets

Drug category: Hypertension medications

Drug classification: Angiotensin II receptor blockers (ARBs)

Pharmaceutical form: Tablets

Pharmaceutical family: Renin-angiotensin-aldosterone system (RAAS) inhibitors

Active ingredient: Losartan

Information about Norvasc tablets

Drug category: Hypertension and angina medications

Drug classification: Calcium channel blockers

Pharmaceutical form: Tablets

Active ingredient: Amlodipine besylate

Author Name: Pharmacist Rawan Mossad Elsaed

Scientific Degree: Pharmacist

Country: Egypt

Dr. Rawan Mosaad El-Saeed is a clinical pharmacist and medical content reviewer holding a Bachelor of Pharmacy degree from Horus University in Egypt. She has hands-on community pharmacy experience in providing medication therapy counseling, monitoring drug-drug interactions, and ensuring patient adherence to safe usage protocols. She specializes in authoring and fact-checking pharmaceutical guides and simplifying clinical pharmacology based on the latest evidence-based guidelines and internationally accredited references, dedicated to delivering accurate, reliable, and safe healthcare information for readers.

Published Date: 16 April 2025